¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cytotropic anaphylaxis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® anaphylaxis ÇÑ±Û ¾Æ³ªÇʶô½Ã½º, °ú¹ÎÁõ
¼³¸í   
  ¾Æ³ªÇʶô½Ã½º¶ó´Â ¸»Àº Á¦ 1Çü °ú¹Î¹ÝÀÀ°ú °°Àº ¸»·Î ¿Ü°èÀÇ ¹°Áú¿¡ ´ëÇÑ ¸é¿ª ¹ÝÀÀÀÌ Áö³ªÄ¡°Ô Ç×ÁøµÇ¾î Àִ º´ÀûÀΠ»óŸ¦ ¸»ÇÑ´Ù. ¸é¿ªÀ̶õ ¿ÜºÎ¹°Áú¿¡ ´ëÇÑ ¹æ¾î¸¦ ¸ñÀûÀ¸·Î Çϴ ¼¼Æ÷µéÀǠȰµ¿À» ÀǹÌÇϸç, ¿©±â¿¡´Â Ç×üÀÇ Çü¼º, ¼¼Æ÷µéÀÇ Æ÷½ÄÀÛ¿ë(¿ÜºÎ¿¡¼­ µé¾î¿Â ¹°ÁúÀ» ¸é¿ª±â´ÉÀ» Çϴ ¼¼Æ÷°¡ Àâ¾Æ¸Ô´Â °Í)µîÀÌ Æ÷ÇԵȴÙ. Ç×üÀÇ Çü¼ºÀº ¿ÜºÎ·ÎºÎÅÍ µé¾î¿Â ¹°ÁúÀ» ¿ì¼± Å«Æ÷½Ä¼¼Æ÷ µîÀÌ Æ÷½ÄÀ» Çϰí À̰Ϳ¡ ´ëÇÑ Á¤º¸¸¦ T-¸²ÇÁ±¸¿¡°Ô Àü´ÞÇϰí T-¸²ÇÁ±¸´Â ÀÌ Á¤º¸¸¦ Ã³¸®ÇÏ¿© Áý¾àµÈ Á¤º¸¸¦ B-¸²ÇÁ±¸¿¡°Ô Àü´ÞÇϸç ÀÌ ¼¼Æ÷·Î ÇÏ¿©±Ý ±× ¹°Áú ¿¡ ´ëÇÑ Ç×ü¸¦ »ý¼ºÇϰԠÇÑ´Ù. Ç×ü´Â ¿ÜºÎÀÇ ¹°Áú°ú Á¤È®È÷ °áÇÕÇÏ¿© ¿ÜºÎÀÇ ¹°ÁúÀǠȰ¼ºÈ­¸¦ ¾ø¾Ö´Â ¹°ÁúÀÌ´Ù. ÀÌ·¸°Ô Çü¼ºµÈ Ç×üÁß¿¡¼­ IgE¿¡ ºÎÂøµÉ ¼ö ÀÖ´Â, Áï À̹̠Ç×ü IgE°¡ Çü¼ºµÈ(ÀÌ·¸°Ô µÇ±â À§Çؼ­´Â ±× ¹°ÁúÀÌ ÀÌÀü¿¡ ÇÑ ¹ø ¸ö¼Ó¿¡ µé¾î ¿Ô¾î¾ß ÇÑ´Ù) ¹°ÁúÀÌ È÷½ºÅ¸¹Î µîÀÇ ¿©·¯ ¹°ÁúÀÌ ³ª¿À°Ô µÇ°í ÀÌ·± ¹°Áúµé¿¡ ÀÇÇØ¼­ »ý±â´Â ¿©·¯ °¡Áö ½Åü¿¡ ÇطοÝÀÀÀÌ »ý°Ü³­´Ù. ±×·¡¼­ ÇÊ¿ä ÀÌ»óÀ¸·Î °ú¹ÎÇÑ ÀÌ·¯ÇÑ ÇüÅÂÀÇ ¸é¿ªÀÛ¿ëÀ» °ÅÄ¡´Â ¹ÝÀÀÀ» ¾Æ´ÏÇʶô½Ã½º¶ó ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotropic
    ¼¼Æ÷ģȭ¼º-
  • cytotropic antibody
    ¼¼Æ÷ģȭÇ×ü
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã½º
  • exercise-induced anaphylaxis
    ¿îµ¿À¯¹ß¾Æ³ªÇʶô½Ã½º
  • generalized anaphylaxis
    Àü½Å¾Æ³ªÇʶô½Ã½º
  • local anaphylaxis
    ±¹¼Ò¾Æ³ªÇʶô½Ã½º
  • passive cutaneous anaphylaxis
    ¼öµ¿ÇǺξƳªÇʶô½Ã½º
  • reverse passive anaphylaxis
    ¿ª¼öµ¿¾Æ³ªÇʶô½Ã½º
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã½º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotropic antibody
    ¼¼Æ÷ģȭÇ×ü
  • cytotropic
    ¼¼Æ÷ģȭ¼º-
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã½º
  • exercise-induced anaphylaxis
    ¿îµ¿À¯µµ¾Æ³ªÇʶô½Ã½º
  • generalized anaphylaxis
    Àü½Å¾Æ³ªÇʶô½Ã½º
  • local anaphylaxis
    ±¹¼Ò¾Æ³ªÇʶô½Ã½º
  • passive cutaneous anaphylaxis
    ¼öµ¿ÇǺξƳªÇʶô½Ã½º
  • reverse passive anaphylaxis
    ¿ª¼öµ¿¾Æ³ªÇʶô½Ã½º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody, cytotropic
    ¼¼Æ÷ģȭ¼ºÇ×ü
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã.
  • anaphylaxis
    ¾Æ´ÏÇʶô½Ã
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã½º
  • anaphylaxis
    °ú¹ÎÁõ, ¾Æ³ªÇʶô½Ã½º
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã½º, °ú¹ÎÁõ(ΦÚÂñø)
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã½º.
  • anaphylaxis,arachidonic acid metabolitesin
    ¾Æ¶ó۵·»ê ´ë»ç¹°Áú(¡­ß« ÓÛÞóÚªòõ)
  • antiserum anaphylaxis
    Ç×Ç÷û¾Æ³ªÇʶô½Ã.
  • antiserum anaphylaxis
    Ç×Ç÷û¾Æ³ªÇʶô½Ã½º.
  • generalized anaphylaxis
    Àü½Å¾Æ³ªÇʶô ½Ã½º.
  • generalized anaphylaxis
    Àü½Å ¾Æ³ªÇʶô½Ã½º
  • heterologous anaphylaxis
    ÀÌÁ¾¾Æ³ªÇʶô½Ã.
  • histamine, anaphylaxis
    È÷½ºÅ¸¹Î, ¾Æ³ªÆÈ¶ô½Ã¼º
  • homologous anaphylaxis
    µ¿Á¾(ÔÒðú)¾Æ³ªÇʶô½Ã.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody, cytotropic
    ¼¼Æ÷ģȭ¼ºÇ×ü
  • cytotropic
    ¼¼Æ÷ÁöÇ⼺(á¬øàò¦ú¾àõ).
  • cytotropic
    ¼¼Æ÷ģȭ¼ºÀÇ
  • cytotropic antibody
    ¼¼Æ÷ģȭ¼ºÇ×ü.
  • anaphylaxis
    °ú¹ÎÁõ, ¾Æ³ªÇʶô½Ã½º
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã½º, °ú¹ÎÁõ(ΦÚÂñø)
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã½º.
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã.
  • anaphylaxis
    ¾Æ´ÏÇʶô½Ã
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã½º
  • anaphylaxis,arachidonic acid metabolitesin
    ¾Æ¶ó۵·»ê ´ë»ç¹°Áú(¡­ß« ÓÛÞóÚªòõ)
  • antiserum anaphylaxis
    Ç×Ç÷û¾Æ³ªÇʶô½Ã.
  • antiserum anaphylaxis
    Ç×Ç÷û¾Æ³ªÇʶô½Ã½º.
  • cutaneous anaphylaxis
    ÇǺξƳªÇʶô½Ã.
  • cutaneous anaphylaxis
    ÇǺξƳªÇʶô½Ã½º
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotropic anaphylaxis
    Çâ¼¼Æ÷(ù÷á¬øà) ¾Æ³ªÇʶô½Ã½º
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotropic antibody
    ¼¼Æ÷ģȭ¼º Ç×ü(á¬øàöÑûúàõù÷ô÷)
  • active anaphylaxis
    Ȱ¼º(üÀàõ)¾Æ³ªÇʶô½Ã½º
  • aggregate anaphylaxis
    ÀÀÁý(ëêó¢)¾Æ³ªÇʶô½Ã½º
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã½º
  • cytotoxic anaphylaxis
    ¼¼Æ÷µ¶¼º(á¬øàÔ¸àõ) ¾Æ³ªÇʶô½Ã½º
  • passive anaphylaxis
    ¼öµ¿(áôÔÑ) ¾Æ³ªÇʶô½Ã½º
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã, °ú¹ÎÁõ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SRS-A Slow Reacting Substance of Anaphylaxis
ASA acetylsalicylic acid; active systemic anaphylaxis; Adams-Stokes attack; American Society of Anesthes...
BK-A basophil kallikrein of anaphylaxis
ECFA, ECF-A eosinophilic chemotactic factor of anaphylaxis
PAF-A platelet-activating factor of anaphylaxis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ACA Active cutaneous anaphylaxis
IA Idiopathic Anaphylaxis
PCA Passive Cutaneous Anaphylaxis
SRS-A Slow Reacting Substance of Anaphylaxis
ASA active systemic anaphylaxis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • heterologous anaphylaxis
    ÀÌÁ¾ ¾Æ³ªÇʶô½Ã
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
cytotropic Having an affinity for cells.
Synonym: cytophilic.
(05 Mar 2000)
cytotropic antibody Antibody that has an affinity for certain kinds of cells, in addition to and unrelated to its specific affinity for the antigen that induced it, because of the properties of the Fc portion of the heavy chain.
See: heterocytotropic antibody, homocytotropic antibody, cytotropic antibody test.
Synonym: anaphylactic antibody, cytophilic antibody.
(05 Mar 2000)
cytotropic antibody test A rosette test for macrophage cytotropic antibody: monolayers of macrophages are exposed first to antibody cytotropic for macrophages, then to the antigen (for which the antibody is specific), and indicator sheep erythrocytes; if the antibody is specific for sheep erythrocytes, the latter will form a rosette around the macrophages directly, but if not, and the antigen is soluble, the antigen must be coupled to the sheep erythrocytes by an agent such as bis-diazotised benzidine.
(05 Mar 2000)
active anaphylaxis Reaction following inoculation of antigen in a subject previously sensitised to the specific antigen, in contrast to passive anaphylaxis.
(05 Mar 2000)
aggregate anaphylaxis <pharmacology> As opposed to prophylaxis. A system or treatment that leads to damaging effects on the organism.
<immunology> Now reserved for those inflammatory reactions resulting from combination of a soluble antigen with IgE bound to a mast cell that leads to degranulation of the mast cell and release of histamine and histamine like substances, causing localised or global immune reponses.
Results in an acute allergic reaction with shortness of breath, rash, wheezing, hypotension.
See: hypersensitivity.
(18 Nov 1997)
anaphylaxis <pharmacology> As opposed to prophylaxis. A system or treatment that leads to damaging effects on the organism.
<immunology> Now reserved for those inflammatory reactions resulting from combination of a soluble antigen with IgE bound to a mast cell that leads to degranulation of the mast cell and release of histamine and histamine like substances, causing localised or global immune reponses.
Results in an acute allergic reaction with shortness of breath, rash, wheezing, hypotension.
See: hypersensitivity.
(18 Nov 1997)
antiserum anaphylaxis A reaction resulting from inoculation of antigen in an animal previously inoculated intravenously with specific antiserum from another animal, a latent period being required between the two inoculations.
Synonym: antiserum anaphylaxis.
(05 Mar 2000)
generalised anaphylaxis The immediate response, involving smooth muscles and capillaries throughout the body of a sensitised individual, that follows intravenous (and occasionally intracutaneous) injection of antigen (allergen).
See: anaphylactic shock.
Synonym: systemic anaphylaxis.
(05 Mar 2000)
passive anaphylaxis A reaction resulting from inoculation of antigen in an animal previously inoculated intravenously with specific antiserum from another animal, a latent period being required between the two inoculations.
Synonym: antiserum anaphylaxis.
(05 Mar 2000)
passive cutaneous anaphylaxis An evanescent cutaneous reaction occurring when antibody is injected into a local area on the skin and antigen is subsequently injected intravenously along with a dye. The dye makes the rapidly occurring capillary dilatation and increased vascular permeability readily visible by leakage into the reaction site. Pca is a sensitive reaction for detecting very small quantities of antibodies and is also a method for studying the mechanisms of immediate hypersensitivity.
(12 Dec 1998)
passive cutaneous anaphylaxis test An animal is injected intradermally with antibody (usually IgE) and subsequently challenged intravenously with a mixture of antigen and Evans blue dye 24-48 hours later. A dark blue area indicates a positive reaction due to the leakage of the dye at the site of antigen-antibody reactions.
(05 Mar 2000)
reversed anaphylaxis An anaphylactic reaction induced in an animal injected with a specific antigen, which will bind to reactive tissue, and then, after a latent period, with serum from another animal previously sensitised to the identical antigen.
Synonym: reversed anaphylaxis.
(05 Mar 2000)
reversed passive anaphylaxis An anaphylactic reaction induced in an animal injected with a specific antigen, which will bind to reactive tissue, and then, after a latent period, with serum from another animal previously sensitised to the identical antigen.
Synonym: reversed anaphylaxis.
(05 Mar 2000)
pharmacologic mediators of anaphylaxis Substances released from mast (and other) cells by the reaction of antigen and specific homocytotropic antibody on their surfaces; they include histamine, slow-reacting substance of anaphylaxis (SRS-A), bradykinin, and (in some species of animals) serotonin.
(05 Mar 2000)
chronic anaphylaxis A haemorrhagic and necrotizing inflammation developing in the ileum (and also the colon) of sensitised dogs when they are fed a second dose of the sensitizing material.
Synonym: chronic anaphylaxis.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • anaphylaxis
    °ú¹ÎÁõ(°ú´Ô¼º)ÀÇ;¾Æ³ªÇʶô½Ã½ºÀÇ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á